Valuation: Antengene Corporation Limited

Market Cap 1.65B 1.94B 248M 222M 205M 186M 347M 23.58B 352M 2.46B 978M 12.34B 929M 909M 39.17B P/E 2026 *
4.53x
P/E 2027 * -18.5x
Enterprise Value 1.65B 1.94B 248M 222M 205M 186M 347M 23.58B 352M 2.46B 978M 12.34B 929M 909M 39.17B EV / Sales 2026 *
1.99x
EV / Sales 2027 * 4.89x
Free-Float
62.81%
Yield 2026 *
-
Yield 2027 * -
1 day-0.53%
1 week-6.30%
Current month-18.35%
1 month-15.92%
3 months-32.58%
6 months-44.28%
Current year-25.46%
1 week 2.7
Extreme 2.705
3.02
1 month 2.7
Extreme 2.705
3.54
Current year 2.7
Extreme 2.705
6.28
1 year 2.7
Extreme 2.705
6.28
3 years 0.5
Extreme 0.5
8.16
5 years 0.5
Extreme 0.5
13.06
10 years 0.5
Extreme 0.5
22.5
Manager TitleAgeSince
Chief Executive Officer 60 27/08/2018
Chief Tech/Sci/R&D Officer 42 19/05/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 60 27/08/2018
Director/Board Member 51 08/11/2020
Director/Board Member 59 13/04/2023
Date Insider Type Main position Quantity % Market Cap. Importance
10/09/26 Other

Director

200,000 0.0294%
10/09/26 Other 2,000,000 0.2944%
10/09/26 Other

Director

200,000 0.0294%
Change 5-day change 1-year change 3-year change Capi.($)
-0.53%-6.30%-42.58%+124.21% 249M
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.68%+12.25%+83.90% 55.53B
+1.48%+1.72%+12.98%+105.14% 53.03B
-0.65%-0.21%+27.50%+56.77% 45.99B
-0.40%-2.72%+18.11%+99.27% 42.45B
+0.44%+0.98%+226.67%+932.89% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+42.73%+103.77%+90.26% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.35%+2.86%+42.96%+159.30% 39.28B
Weighted average by Cap. -0.06%+3.13%+49.48%+160.83%

Financials

2026 *2027 *
Net sales 830M 977M 125M 112M 103M 93.56M 175M 11.86B 177M 1.24B 492M 6.21B 467M 457M 19.7B 338M 397M 50.65M 45.45M 42.02M 38.05M 71.09M 4.82B 71.95M 502M 200M 2.52B 190M 186M 8.01B
Net income 333M 392M 49.98M 44.84M 41.46M 37.55M 70.15M 4.76B 71M 496M 197M 2.49B 188M 184M 7.91B -84.79M -99.77M -12.72M -11.41M -10.55M -9.55M -17.85M -1.21B -18.06M -126M -50.24M -634M -47.72M -46.72M -2.01B
Net Debt - -
Projected Income Statement - Annual - Antengene Corporation Limited
Logo Antengene Corporation Limited
Antengene Corp Ltd is a clinical-stage Asia-Pacific biopharmaceutical company focused on innovative oncology medicines. The Company is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company's products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The Company mainly conducts its business in Asia-Pacific.
Employees
122
Date Price Change Volume
29/10/26 HK$2.825 -0.53% 282,000
28/10/26 HK$2.840 +2.34% 1,049,500
27/10/26 HK$2.775 -5.61% 1,096,500
26/10/26 HK$2.940 +1.91% 338,000
23/10/26 HK$2.885 +1.58% 829,000
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.401CNY
Average target price
4.150CNY
Spread / Average Target
+72.86%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Antengene Corporation Limited
  1. Stock Market
  2. Stocks
  3. 6996 Stock